The Week That Was, 27 Oct 2014
As usual in the life science universe, there were a number of “reactions” to market forces over the last week. Shire is to remain independent as AbbVie bows to the growing aversion to inversion strategies, a somewhat short-lived financial strategy that spawned a slew of major potential acquisitions for tax purposes including Pfizer’s earlier pursuit […]
The Week That Was, 27 Oct 2014 Read More »